{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:21:23Z","timestamp":1794590483616,"version":"4.9.1"},"reference-count":39,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,2,14]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>We have created a new highly active chimeric antigen receptor (CAR) specific for CD22. The design of new CARs may benefit more from target antigen epitope selection than from optimizing affinity.<\/jats:p>","DOI":"10.1182\/blood-2012-06-438002","type":"journal-article","created":{"date-parts":[[2012,12,15]],"date-time":"2012-12-15T20:46:10Z","timestamp":1355604370000},"page":"1165-1174","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":510,"title":["Anti-CD22\u2013chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"121","author":[{"given":"Waleed","family":"Haso","sequence":"first","affiliation":[{"name":"Pediatric Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Lee","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirali N.","family":"Shah","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryalice","family":"Stetler-Stevenson","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance M.","family":"Yuan","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira H.","family":"Pastan","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology, CCR, NCI, NIH, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimiter S.","family":"Dimitrov","sequence":"additional","affiliation":[{"name":"CCR Nanobiology Program, Frederick National Lab, Frederick, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Morgan","sequence":"additional","affiliation":[{"name":"Surgery Branch, CCR, NCI, NIH, Bethesda, MD; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"FitzGerald","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology, CCR, NCI, NIH, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Barrett","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation Program, Children's Hospital of Pennsylvania, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan S.","family":"Wayne","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD;"},{"name":"Laboratory of Molecular Biology, CCR, NCI, NIH, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal L.","family":"Mackall","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimas J.","family":"Orentas","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2019111820583135800_B1","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMra052603","article-title":"Treatment of acute lymphoblastic leukemia.","volume":"354","author":"Pui","year":"2006","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111820583135800_B2","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1200\/JCO.2010.30.1382","article-title":"Modern therapy of acute lymphoblastic leukemia.","volume":"29","author":"Bassan","year":"2011","journal-title":"J Clin Oncol"},{"issue":"18","key":"2019111820583135800_B3","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1093\/jnci\/djn306","article-title":"Progress in the curative treatment of childhood hematologic malignancies.","volume":"100","author":"Wayne","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"31","key":"2019111820583135800_B4","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1200\/JCO.2012.41.6768","article-title":"Monoclonal Antibody-Based Therapies: A New Dawn in the Treatment of Acute Lymphoblastic Leukemia.","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111820583135800_B5","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1158\/1078-0432.CCR-11-1920","article-title":"The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer.","volume":"18","author":"Lee","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"95","key":"2019111820583135800_B6","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"issue":"12","key":"2019111820583135800_B7","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"issue":"19","key":"2019111820583135800_B8","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1182\/blood-2010-01-265041","article-title":"Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2019111820583135800_B9","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"issue":"18","key":"2019111820583135800_B10","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"issue":"24","key":"2019111820583135800_B11","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","article-title":"Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.","volume":"28","author":"Thomas","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111820583135800_B12","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1600-065X.2009.00801.x","article-title":"CD22 and Siglec-G: B-cell inhibitory receptors with distinct functions.","volume":"230","author":"Nitschke","year":"2009","journal-title":"Immunol Rev"},{"issue":"20","key":"2019111820583135800_B13","doi-asserted-by":"crossref","first-page":"6300","DOI":"10.1158\/0008-5472.CAN-11-1374","article-title":"Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.","volume":"71","author":"FitzGerald","year":"2011","journal-title":"Cancer Res"},{"issue":"5","key":"2019111820583135800_B14","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood.V90.5.2020","article-title":"Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors.","volume":"90","author":"Mansfield","year":"1997","journal-title":"Blood"},{"issue":"4","key":"2019111820583135800_B15","first-page":"995","article-title":"Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.","volume":"8","author":"Salvatore","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2019111820583135800_B16","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1158\/1078-0432.CCR-09-2980","article-title":"Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial.","volume":"16","author":"Wayne","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2019111820583135800_B17","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2141.2010.08251.x","article-title":"Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia.","volume":"150","author":"Mussai","year":"2010","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111820583135800_B18","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4161\/mabs.1.3.8113","article-title":"Identification and characterization of fully human anti-CD22 monoclonal antibodies.","volume":"1","author":"Xiao","year":"2009","journal-title":"mAbs"},{"issue":"7","key":"2019111820583135800_B19","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/CJI.0b013e3181ac6138","article-title":"Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.","volume":"32","author":"Kochenderfer","year":"2009","journal-title":"J Immunother"},{"issue":"1","key":"2019111820583135800_B20","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1074\/jbc.M409783200","article-title":"In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin.","volume":"280","author":"Ho","year":"2005","journal-title":"J Biol Chem"},{"issue":"9","key":"2019111820583135800_B21","doi-asserted-by":"crossref","first-page":"5563","DOI":"10.4049\/jimmunol.0900447","article-title":"A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced t lymphocytes and antitumor activity.","volume":"183","author":"Zhao","year":"2009","journal-title":"J Immunol"},{"issue":"20","key":"2019111820583135800_B22","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-11-0487","article-title":"Antibody Fusion Proteins: Anti-CD22 recombinant immunotoxin moxetumomab pasudotox.","volume":"17","author":"Kreitman","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2019111820583135800_B23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1479-5876-10-29","article-title":"Protein L: a novel reagent for the detection of chimeric antigen receptor (CAR) expression by flow cytometry.","volume":"10","author":"Zheng","year":"2012","journal-title":"J Transl Med"},{"issue":"2","key":"2019111820583135800_B24","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/(SICI)1097-0320(19981001)33:2<106::AID-CYTO4>3.0.CO;2-H","article-title":"Standardizing flow cytometry: a classification system of fluorescence standards used for flow cytometry.","volume":"33","author":"Schwartz","year":"1998","journal-title":"Cytometry"},{"issue":"15","key":"2019111820583135800_B25","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1182\/blood-2011-04-346528","article-title":"Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling.","volume":"118","author":"Barrett","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2019111820583135800_B26","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/01.cji.0000161397.96582.59","article-title":"The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scfvs and antigens.","volume":"28","author":"Guest","year":"2005","journal-title":"J Immunother"},{"issue":"10","key":"2019111820583135800_B27","doi-asserted-by":"crossref","first-page":"7028","DOI":"10.4049\/jimmunol.180.10.7028","article-title":"Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane.","volume":"180","author":"James","year":"2008","journal-title":"J Immunol"},{"issue":"12","key":"2019111820583135800_B28","doi-asserted-by":"crossref","first-page":"7647","DOI":"10.4049\/jimmunol.173.12.7647","article-title":"T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity.","volume":"173","author":"Chmielewski","year":"2004","journal-title":"J Immunol"},{"key":"2019111820583135800_B29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(05)88001-0","article-title":"CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction.","volume":"88","author":"Tedder","year":"2005","journal-title":"Adv Immunol"},{"issue":"14","key":"2019111820583135800_B30","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.2010.33.4623","article-title":"Active and passive immunotherapy for lymphoma: proving principles and improving results.","volume":"29","author":"Brody","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111820583135800_B31","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1158\/1078-0432.CCR-04-1939","article-title":"HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity.","volume":"11","author":"Bang","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2019111820583135800_B32","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/nm1676","article-title":"2007. T cell-encoded CD80 and 4-1BBL induce auto and transcostimulation, resulting in potent tumor rejection.","volume":"13","author":"Stephan","year":"2007","journal-title":"Nat Med"},{"issue":"2","key":"2019111820583135800_B33","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nbt0202-143","article-title":"Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB.","volume":"20","author":"Maus","year":"2002","journal-title":"Nat Biotechnol"},{"issue":"8","key":"2019111820583135800_B34","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.","volume":"17","author":"Milone","year":"2009","journal-title":"Mol Ther"},{"issue":"13","key":"2019111820583135800_B35","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/0008-5472.CAN-11-0422","article-title":"In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB).","volume":"71","author":"Song","year":"2011","journal-title":"Cancer Res"},{"issue":"1","key":"2019111820583135800_B36","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4049\/jimmunol.172.1.104","article-title":"Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain.","volume":"172","author":"Finney","year":"2004","journal-title":"J Immunol"},{"issue":"18","key":"2019111820583135800_B37","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.","volume":"29","author":"Topp","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111820583135800_B38","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1182\/blood-2012-07-441030","article-title":"Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-linage ALL.","volume":"120","author":"Topp","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2019111820583135800_B39","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/leu.2010.184","article-title":"High frequencies of leukemia stem cells in poor-outcome childhood precursor-B acute lymphoblastic leukemias.","volume":"24","author":"Morisot","year":"2010","journal-title":"Leukemia"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/121\/7\/1165\/1367991\/zh800713001165.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/121\/7\/1165\/1367991\/zh800713001165.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T20:58:50Z","timestamp":1574110730000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/121\/7\/1165\/31529\/AntiCD22chimeric-antigen-receptors-targeting-Bcell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,14]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,2,14]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-06-438002","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,14]]}}}